These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
213 related articles for article (PubMed ID: 20200357)
41. Farnesylamine: an inhibitor of farnesylation and growth of ras-transformed cells. Kothapalli R; Guthrie N; Chambers AF; Carroll KK Lipids; 1993 Nov; 28(11):969-73. PubMed ID: 8277827 [TBL] [Abstract][Full Text] [Related]
42. Distinct GAB2 signaling pathways are essential for myeloid and lymphoid transformation and leukemogenesis by BCR-ABL1. Gu S; Chan WW; Mohi G; Rosenbaum J; Sayad A; Lu Z; Virtanen C; Li S; Neel BG; Van Etten RA Blood; 2016 Apr; 127(14):1803-13. PubMed ID: 26773044 [TBL] [Abstract][Full Text] [Related]
43. Artemisinin inhibits NRas palmitoylation by targeting the protein acyltransferase ZDHHC6. Qiu N; Abegg D; Guidi M; Gilmore K; Seeberger PH; Adibekian A Cell Chem Biol; 2022 Mar; 29(3):530-537.e7. PubMed ID: 34358442 [TBL] [Abstract][Full Text] [Related]
44. Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system. Mayotte N; Roy DC; Yao J; Kroon E; Sauvageau G Blood; 2002 Dec; 100(12):4177-84. PubMed ID: 12393433 [TBL] [Abstract][Full Text] [Related]
45. Mutant forms of growth factor-binding protein-2 reverse BCR-ABL-induced transformation. Gishizky ML; Cortez D; Pendergast AM Proc Natl Acad Sci U S A; 1995 Nov; 92(24):10889-93. PubMed ID: 7479904 [TBL] [Abstract][Full Text] [Related]
46. Cooperation of Dnmt3a R878H with Nras G12D promotes leukemogenesis in knock-in mice: a pilot study. Shi X; Yang Y; Shang S; Wu S; Zhang W; Peng L; Huang T; Zhang R; Ren R; Mi J; Wang Y BMC Cancer; 2019 Nov; 19(1):1072. PubMed ID: 31703632 [TBL] [Abstract][Full Text] [Related]
47. A non-farnesylated Ha-Ras protein can be palmitoylated and trigger potent differentiation and transformation. Booden MA; Baker TL; Solski PA; Der CJ; Punke SG; Buss JE J Biol Chem; 1999 Jan; 274(3):1423-31. PubMed ID: 9880516 [TBL] [Abstract][Full Text] [Related]
48. Bisubstrate inhibitors of farnesyltransferase: a novel class of specific inhibitors of ras transformed cells. Manne V; Yan N; Carboni JM; Tuomari AV; Ricca CS; Brown JG; Andahazy ML; Schmidt RJ; Patel D; Zahler R Oncogene; 1995 May; 10(9):1763-79. PubMed ID: 7753553 [TBL] [Abstract][Full Text] [Related]
49. Loss of wild-type Kras promotes activation of all Ras isoforms in oncogenic Kras-induced leukemogenesis. Kong G; Chang YI; Damnernsawad A; You X; Du J; Ranheim EA; Lee W; Ryu MJ; Zhou Y; Xing Y; Chang Q; Burd CE; Zhang J Leukemia; 2016 Jul; 30(7):1542-51. PubMed ID: 27055865 [TBL] [Abstract][Full Text] [Related]
50. RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7. Side LE; Curtiss NP; Teel K; Kratz C; Wang PW; Larson RA; Le Beau MM; Shannon KM Genes Chromosomes Cancer; 2004 Mar; 39(3):217-23. PubMed ID: 14732923 [TBL] [Abstract][Full Text] [Related]
51. RAS gene activation in acute myelogenous leukemia: analysis by in vitro amplification and DNA base sequence determination. Mane SM; Meltzer SJ; Gutheil JC; Kapil V; Lee EJ; Needleman SW Genes Chromosomes Cancer; 1990 May; 2(1):71-7. PubMed ID: 2278967 [TBL] [Abstract][Full Text] [Related]
52. Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance. Lim JKM; Delaidelli A; Minaker SW; Zhang HF; Colovic M; Yang H; Negri GL; von Karstedt S; Lockwood WW; Schaffer P; Leprivier G; Sorensen PH Proc Natl Acad Sci U S A; 2019 May; 116(19):9433-9442. PubMed ID: 31000598 [TBL] [Abstract][Full Text] [Related]
53. Farnesol modification of Kirsten-ras exon 4B protein is essential for transformation. Jackson JH; Cochrane CG; Bourne JR; Solski PA; Buss JE; Der CJ Proc Natl Acad Sci U S A; 1990 Apr; 87(8):3042-6. PubMed ID: 2183224 [TBL] [Abstract][Full Text] [Related]
54. [Farnesyl transferase inhibitors (anti-Ras). A new class of anticancer agents]. Levy R Presse Med; 1995 Apr 15-22; 24(15):725-9. PubMed ID: 7784406 [TBL] [Abstract][Full Text] [Related]
55. The role of palmitoylation in regulating Ras localization and function. Eisenberg S; Laude AJ; Beckett AJ; Mageean CJ; Aran V; Hernandez-Valladares M; Henis YI; Prior IA Biochem Soc Trans; 2013 Feb; 41(1):79-83. PubMed ID: 23356262 [TBL] [Abstract][Full Text] [Related]
56. Correlated flow cytometric analysis of H-ras p21 and DNA ploidy in acute myelogenous leukemia. Lin F; Liu S; Ren J; Wei J; Xu S; Liu R; Yao E J Tongji Med Univ; 1996; 16(2):75-7. PubMed ID: 9275696 [TBL] [Abstract][Full Text] [Related]
57. BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia. Omidvar N; Kogan S; Beurlet S; le Pogam C; Janin A; West R; Noguera ME; Reboul M; Soulie A; Leboeuf C; Setterblad N; Felsher D; Lagasse E; Mohamedali A; Thomas NS; Fenaux P; Fontenay M; Pla M; Mufti GJ; Weissman I; Chomienne C; Padua RA Cancer Res; 2007 Dec; 67(24):11657-67. PubMed ID: 18089795 [TBL] [Abstract][Full Text] [Related]
58. Palmitoylation of R-Ras by human DHHC19, a palmitoyl transferase with a CaaX box. Baumgart F; Corral-Escariz M; Pérez-Gil J; Rodríguez-Crespo I Biochim Biophys Acta; 2010 Mar; 1798(3):592-604. PubMed ID: 20074548 [TBL] [Abstract][Full Text] [Related]
59. Comparison of liver oncogenic potential among human RAS isoforms. Chung SI; Moon H; Ju HL; Kim DY; Cho KJ; Ribback S; Dombrowski F; Calvisi DF; Ro SW Oncotarget; 2016 Feb; 7(6):7354-66. PubMed ID: 26799184 [TBL] [Abstract][Full Text] [Related]
60. Leukemogenesis of b2a2-type p210 BCR/ABL in a bone marrow transplantation mouse model using a lentiviral vector. Uchida N; Hanawa H; Dan K; Inokuchi K; Shimada T J Nippon Med Sch; 2009 Jun; 76(3):134-47. PubMed ID: 19602820 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]